Caris Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	452.5	412.26	306.13	258.49
Revenue Growth (YoY)	-	34.67%	18.43%	-
Cost of Revenue	241.12	231.83	214.87	178.46
Gross Profit	211.38	180.43	91.26	80.02
Selling, General & Admin	334.04	326.05	296.04	294.51
Research & Development	100.19	111.5	114.77	101.27
Operating Expenses	434.23	437.55	410.81	395.78
Operating Income	-222.85	-257.12	-319.55	-315.76
Interest Expense	-53.52	-50.03	-31.61	-26.68
Interest & Investment Income	5.86	7.12	11.26	0.95
Other Non Operating Income (Expenses)	-2.94	18.14	9.4	20.66
EBT Excluding Unusual Items	-273.44	-281.89	-330.5	-320.83
Other Unusual Items	-	-	-10.92	-
Pretax Income	-273.44	-281.89	-341.42	-320.83
Net Income	-273.44	-281.89	-341.42	-320.83
Preferred Dividends & Other Adjustments	97.72	96.37	121.11	79
Net Income to Common	-371.16	-378.26	-462.53	-399.83
Shares Outstanding (Basic)	36	35	35	33
Shares Outstanding (Diluted)	36	35	35	33
Shares Change (YoY)	-	1.59%	4.73%	-
EPS (Basic)	-10.43	-10.66	-13.24	-11.98
EPS (Diluted)	-10.43	-10.66	-13.24	-11.98
Free Cash Flow	-212.01	-253.64	-298.42	-327.96
Free Cash Flow Per Share	-5.96	-7.15	-8.54	-9.83
Gross Margin	46.71%	43.77%	29.81%	30.96%
Operating Margin	-49.25%	-62.37%	-104.38%	-122.16%
Profit Margin	-82.02%	-91.75%	-151.09%	-154.68%
Free Cash Flow Margin	-46.85%	-61.52%	-97.48%	-126.88%
EBITDA	-184.6	-208.21	-270.55	-267.5
EBITDA Margin	-40.79%	-50.50%	-88.38%	-103.49%
D&A For EBITDA	38.25	48.91	49	48.25
EBIT	-222.85	-257.12	-319.55	-315.76
EBIT Margin	-49.25%	-62.37%	-104.38%	-122.16%
Revenue as Reported	452.5	412.26	306.13	258.49
Advertising Expenses	-	1.2	0.6	1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q